HTC
REGN icon

Haverford Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Haverford Trust Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$235K Sell
304
-5
-2% -$3.83K ﹤0.01% 398
2025
Q4 		$239K Buy
+309
New +$210K ﹤0.01% 384
2025
Q2 		– Sell
-344
Closed -$218K – 417
2025
Q1 		$218K Buy
344
+25
+8% +$17.2K ﹤0.01% 380
2024
Q4 		$227K Buy
319
+12
+4% +$10.1K ﹤0.01% 374
2024
Q3 		$323K Buy
307
+22
+8% +$24.5K ﹤0.01% 356
2024
Q2 		$300K Buy
285
+5
+2% +$4.85K ﹤0.01% 360
2024
Q1 		$269K Sell
280
-64
-19% -$60.9K ﹤0.01% 347
2023
Q4 		$302K Buy
344
+21
+7% +$17.3K ﹤0.01% 326
2023
Q3 		$266K Hold
323
– – ﹤0.01% 325
2023
Q2 		$232K Buy
323
+3
+0.9% +$2.31K ﹤0.01% 339
2023
Q1 		$263K Buy
320
+29
+10% +$21.9K ﹤0.01% 328
2022
Q4 		$210K Buy
+291
New +$215K ﹤0.01% 323
2022
Q1 		– Sell
-341
Closed -$215K – 368
2021
Q4 		$215K Buy
341
+1
+0.3% +$615 ﹤0.01% 343
2021
Q3 		$206K Sell
340
-60
-15% -$37.2K ﹤0.01% 348
2021
Q2 		$223K Buy
+400
New +$203K ﹤0.01% 335
2021
Q1 		– Sell
-422
Closed -$204K – 321
2020
Q4 		$204K Buy
422
+22
+6% +$11.9K ﹤0.01% 293
2020
Q3 		$224K Hold
400
– – ﹤0.01% 266
2020
Q2 		$249K Buy
+400
New +$227K ﹤0.01% 257

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Haverford Trust Company's REGN Position: Q1 2026 in Review

Haverford Trust Company reduced its Regeneron Pharmaceuticals (REGN) stake by 1.6% in Q1 2026, selling an estimated $3.83K and leaving 304 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #398.

Haverford Trust Company first reported a position in REGN in Q2 2020 and has held it in 18 quarters since. The position peaked at $323K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Haverford Trust Company held 304 shares of Regeneron Pharmaceuticals worth $235K as of Q1 2026.
  • Haverford Trust Company sold 5 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.83K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Haverford Trust Company's portfolio in Q1 2026, its #398 holding.
  • Haverford Trust Company first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
  • Haverford Trust Company's Regeneron Pharmaceuticals position peaked at $323K in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.